Takeda Pharmaceutical Company Limited

Business Details

The company researches, develops, manufactures, and sells pharmaceutical products in approximately 80 countries, centered on six core business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience. It maintains a strong presence in the U.S., Japan, and Europe, with a focus on addressing unmet medical needs. Revenue for FY2026 (ending March 2026) was ¥4,505,720 million, and the overseas revenue ratio remained at a continued high level. The recognition of a ¥402,544 million provision related to the AMITIZA antitrust litigation caused a substantial deterioration in reported operating profit and net profit for the period, although Core performance remained solid.

Recent Overview

Following a jury verdict in the AMITIZA antitrust litigation, a ¥402,544 million litigation provision was recognized as a subsequent event, resulting in significant deterioration in reported performance

On May 18, 2026 (U.S. Eastern Time), a jury in the U.S. District Court for the District of Massachusetts returned a verdict unfavorable to Takeda in the antitrust litigation concerning AMITIZA (lubiprostone), awarding damages of $884,943,990 (a portion of which is automatically trebled under antitrust law). As this verdict relates to conditions that existed as of March 31, 2026, it was treated as a subsequent event and the FY2026 (ending March 2026) results were revised accordingly. An additional litigation provision of ¥402,544 million was recognized within other operating expenses in the consolidated income statement, along with a related tax benefit of ¥58,393 million. As a result, revised operating profit was ¥6,217 million (versus ¥408,761 million before revision), and net loss attributable to owners of the company was -¥152,390 million (versus ¥191,762 million before revision). This revision does not affect Core performance, and there is no change to the FY2025 year-end dividend (¥100 per share) or to the FY2026 earnings forecast and management guidance. The company plans to file post-verdict motions and an appeal, and intends to seek a stay of enforcement of the judgment while the appeal is pending. Separately, in reported FY2026 (ending March 2026) results, Neuroscience revenue continued to decline sharply (-26.8% AER) due to generic penetration of VYVANSE, while Gastroenterology (+3.7% AER), Plasma-Derived Therapies (+2.4% AER), and Oncology (+3.5% AER) maintained revenue growth. Core Operating Profit rose year-on-year to ¥1,172,500 million (+0.8% AER), and Core EPS improved to ¥517 (+5.2% AER).

Key Products

Growth Drivers

• Continued growth in Gastroenterology driven by expanded use of the ENTYVIO subcutaneous formulation (+3.7% AER for FY2026, ending March 2026) and solid demand expansion for the eosinophilic esophagitis treatment EOHILIA in the U.S.
• Increased revenue in Plasma-Derived Therapies (+2.4% AER) driven by expanding demand for immunoglobulin products (HYQVIA, CUVITRU)
• Expanding market penetration of Rare Diseases growth products such as LIVTENCITY (+42.2% AER), ADZYNMA (+68.8% AER), and VONVENDI (+20.8% AER)
• Geographic expansion of oncology products such as FRUZAQLA and ADCETRIS into Europe and Growth & Emerging Markets (total Oncology +3.5% AER)
• Accelerating adoption of QDENGA in dengue-endemic countries (+14.6% AER)
• Substantial decrease in intangible asset amortization expense from FY2027 (ending March 2027) onward following the January 2026 conclusion of amortization related to VYVANSE/ELVANSE (FY2026, ending March 2026 forecast: -¥413.5 billion, down ¥90.8 billion year-on-year)
• Favorable Phase 3 clinical trial results for three late-stage pipeline products (oveporexton, rusfertide, and zasocitinib), each with multi-billion-dollar revenue potential
• Strengthened cost discipline through a transformation program targeting annualized cost savings of over ¥200 billion by fiscal year 2028
• Continued solid demand for TAKECAB/VOCINTI in China and Japan (+9.9% AER)

Risks

• Substantial decline in Neuroscience revenue due to continued generic penetration of VYVANSE in the U.S. (-26.8% AER in FY2026, ending March 2026), with effects expected to continue into FY2027 (ending March 2027) and beyond
• AMITIZA antitrust litigation risk: a jury verdict awarded damages of $884,943,990 (partially subject to trebling), with the final liability amount not yet determined; additional financial burden may arise depending on the outcome of post-verdict motions and appeal
• Pricing pressure on U.S. products (affecting GAMMAGARD LIQUID/KIOVIG, FRUZAQLA, and others) due to Medicare Part D redesign and expansion of the 340B program
• Foreign exchange risk (approximately 90% of revenue is generated overseas, with significant exposure to the U.S. dollar and euro; in FY2026 (ending March 2026), yen appreciation against the U.S. dollar had an impact of over ¥100 billion on U.S. revenue)
• Impairment risk related to goodwill and intangible assets (balances at end of FY2026, ending March 2026: goodwill ¥5,809,010 million, intangible assets ¥3,419,348 million); impairment losses were recognized during the period for the gamma-delta T-cell therapy platform (¥58.2 billion) and ALUNBRIG (¥31.9 billion), among others
• Adjusted net interest-bearing debt remained at a high level of ¥3,817,600 million (end of FY2026, ending March 2026), posing risk of increased financial costs from rising interest rates and foreign exchange fluctuations
• Revenue pressure within Gastroenterology from generic entry for RESOLOR/MOTEGRITY in the U.S. (multiple entrants since January 2025)
• Risk related to stable procurement of source plasma for Plasma-Derived Therapies and intensifying competition from recombinant products such as ADVATE (ADVATE -16.6% AER)
• Risk of tariff measures on pharmaceutical imports from the EU and Japan into the U.S. (geopolitical fragmentation and trade policy uncertainty)
• Impact on the vaccines business from the continued temporary suspension of MR vaccine shipments in Japan
• Uncertainty regarding regulatory approval of late-stage pipeline products (oveporexton, rusfertide, zasocitinib, etc.)